SIDE EFFECTS OF VACCINE ADJUVANTS:
- Toxicity and adjuvant activity must be balanced to obtain maximum immune stimulation with minimal adverse effects.
Majority of adjuvants produce some effects like:-
The inflammatory response
Local pain and tissue lysis
Granulomas and hypersensitivity reactions
Real & Theoretical risks of Vaccine Adjutants:
- Local acute or chronic inflammation with formation of painful abscess, persistent nodules, ulcers or draining lymphadenopathy.
- Induction of influenza like illness, with fever, malaise, myalgia arthralgic or headache.
- Systemic clinical toxicity to tissues or organs.
- Induction of hypersensitivity to host tissue, producing autoimmune arthritis, amyloidosis, anterior uveitis.
- Cross reactions with human antigens, such as glomerular basement membranes or neurolemma, causing glomerulo-nephritis or meningoencephalitis.
- Sensitization to tuberculin or other skin test antigens.
- Carcinogenesis; Teratogenesis; Abortogenesis
- Dissemination of live vector within the host to cause disease; spread of the vector to the environment and other persons.
SAFETY EVALUATION OF VACCINE ADJUVANTS:-
It is a generally accepted principle that toxicity and adjuvant activity must be balanced to obtain maximum immune stimulation with minimal adverse effects.However, the actual acceptance level for adverse reactions depends on whether the adjuvant is intended for use in human or veterinary vaccines. For veterinary applications the acceptance level depends on whether the animal is a companion animal or a livestock animal bred for human consumption.
The safety documentation requirements for adjuvants used in human vaccines are, for obvious reasons, higher. When used in preventive medicine the vaccine is administered to healthy persons and in many cases, as part of vaccination programs for children. Here adverse reactions to the adjuvant are not acceptable.
With therapeutic vaccines, however, a compromise is not unrealistic. Were therapeutic vaccines against serious human diseases (e.g., HIV/AIDS or cancer) or therapeutic vaccines against viral infections (e.g., HTLV-I or hepatitis C) to be developed that required the help of strong adjuvants to be effective, less strict levels of acceptance for the adjuvant side effects may be acceptable.
It would be a question of balancing the profile of vaccination side effects against the general prognosis for the disease if untreated or treated by other therapeutic regimens, many of which themselves are not without side effects.
MECHANISMS BEHIND ADJUVANT SIDE EFFECTS:-
The majority of adjutants produce some effects at the injection site, the most frequent being an infl ammatory response. For the better tolerated adjuvants, used in practical vaccination, by far the majority of cases lead to transient and negligible symptoms only: mild pain, transient swellings, and so on. However, among more than 100 different compounds, described as adjuvants in the literature, the vast majority have been shown to be too reactogenic to be used in human as well as veterinary applications. Such adjuvant active substances may nevertheless be valuable tools for studying the immune system as such, including side effects from excessive stimulation of the immune system.
The mechanisms behind adjuvant side effects, as described below, comprise both observations from the investigation of such highly reactogenic adjuvants (or cytokines) and observations from signifi cant overdosing of classical adjuvants.
Local reactions seen after the use of such adjuvants may range from local pain and erythemas to granulomas, cysts, abscesses, and ulcers, particularly if overdosing the adjuvant beyond the acceptable dose ranges.Adverse systemic reactions due to adjuvant- or cytokine-induced stimulation of the immune system, including pyrogenicity , flu like symptoms, and auto immune disorders, are known from experimental immunology, but are, of course, disqualifying for use of the adjuvant in practical vaccination. A number of observations of side effects seen after vaccination with adjuvanted vaccines must, however, be attributed to the vaccine preservatives (e.g., thiomersal, β-propriolactone, or formaldehyde) or, as mentioned, to bacterial toxins from the antigen preparation.
Local Reactions: Effect of the Injection Modus
Vaccinations may be given subcutaneously or intramuscularly. Other administration routes, such as the intraperitoneal route known from experimental immunology, are not used in practical parenteral vaccination. Oral vaccination of humans has been practiced against poliovirus since the 1960s, but this vaccine is not adjuvanted. Quillaja saponin has been used as an adjuvant for oral experimental vaccines and is accepted as a food additive in Europe under code E999 due to low oral toxicity. Hence, the potential of using Q. saponin as an adjuvant for oral immunizations is yet to be explored. Nasal immunization may have a future in practical vaccination but is still at the developmental stage.
The injection modus is not without importance in relation to local reactogenicity.
When immunizing by the subcutaneous route the vaccine inoculum is introduced into a compartment with numerous sensory neurons (in contrast to the intramuscular compartment). The introduction of a local inflammatory response here may more easily give rise to irritation, itching reactions, and local pain. Also, a transient swelling, as a consequence of the inflammatory focus formed, may be palpable more easily through the skin. After immunizing by the intramuscular route, even a lot of similar size swelling may be less easily visible and palpable, as it is located in deeper-lying tissue. Some
adjuvants (e.g., Q. saponin) which show acceptable safety profiles when administered intramuscularly or subcutaneously in rodents, may cause chemical peritonitis and induce fibrous adherences in the body cavity when injected intraperitoneally.
Local Reactions: The Inflammatory Focus of Adjuvants
Mineral adjuvants (aluminum- and calcium-based adjuvants) should, along with water-in-oil emulsions, (Freund’s-type emulsion adjuvants) be regarded as depot-forming or repository adjuvants. With these adjuvants the formation of a temporary inflammatory focus attracting immunocompetent cells shortly after injection must, more or less, be expected .Upon injection, phagocytic cells and APCs are attracted to the site to phagocytize and clear the inoculum.
The local reaction may be negligible if the inoculum is dispersed rapidly from the injection site. However, if the inoculum resides for a prolonged period of time at the injection site (as is the case with repository adjuvants) then in situ accumulation of phagocytic and immunocompetent cells may in some cases manifest itself as an inflammatory focus accompanied by transient swelling, local irritation, and redness. There are observations of aluminum-adsorbed vaccines giving lead to more local reactions than unadsorbed vaccines with plain toxoid this could in part be explained by the plain toxoid vaccine being dispersed from the injection site before a local reaction was established.
Any visible or palpable reaction at the injection site is in principle non grata, as it hinders the obtaining of a hypothetical and non-reactogenic “ideal adjuvant.” However, it is important to realize that the mechanisms described are part of a normally functioning immune system. Hence, it may not be achievable to use repository adjuvants without temporarily also inducing an inflammatory focus around the inoculum.
Attempts have been made in recent years to link the presence of a local infl ammatory focus in the myofascii [the condition is referred to as macrophagic myofasciitis (MMF)] after intramuscular injections of aluminumadjuvanted vaccines to such conditions as myalgia and muscle fatigue, but also to neurological disorders with no obvious etiological relation to the vaccination Such correlations are, however, associated with statistical problems. There is very high vaccination coverage in Western countries. Hence, it is expected statistically that patients as suffering from a wide range of etiologically unrelated diseases would all have been vaccinated with aluminum-containing vaccines at some point in their medical history. Another problem is that adequate statistical control groups of non vaccinated persons may be hard to find in the same population.
In a recently published controlled study in primates by Verdier and coworkers in France, it was not possible to detect any histological changes after injection of aluminum-adjuvanted vaccine besides the local inflammatory focus itself, and they found no abnormal clinical signs associated to it.
- Adjuvants are essential for the development of new and improved vaccines.
- The development of successful vaccine adjuvants has been a constant balancing act between safety and immunogenicity, delivery and immunostimulation.
- The design and selection of new adjuvants will have to face some major hurdles like:-
– Understanding of the mechanisms of adjuvanticity,
– Development of appropriate delivery systems.